Advertisement

Clinical Journal of Gastroenterology

, Volume 12, Issue 2, pp 120–127 | Cite as

Occurrence of hepatocellular carcinoma 24 years after successful interferon therapy in a patient with chronic hepatitis C: a case report

  • Yuichi YoshidaEmail author
  • Miki Yonezawa
  • Takuya Okamoto
  • Yudai Fujiwara
  • Akiko Suzuki
  • Yuji Suzuki
  • Kei Endo
  • Keisuke Kakisaka
  • Takayoshi Oikawa
  • Hidekatsu Kuroda
  • Akio Miyasaka
  • Yasuhiro Takikawa
Case Report
  • 84 Downloads

Abstract

An 82-year-old man presented with hepatocellular carcinomas (HCCs) 24 years after achieving a sustained virological response (SVR) to an interferon for hepatitis C. His hepatic fibrosis stage was F1 when he was treated at 58 years. He was followed-up by annual blood tests and abdominal ultrasonography or computed tomography. After the IFN treatment, he had drunk approximately 100 g of ethanol. Serum aspartate aminotransferase and gamma-glutamyl transpeptidase levels had been elevated since 2012. To investigate the possible factors that affect hepatocarcinogenesis over 10 years after achieving an SVR, we reviewed the literature. Of 39 reported patients, 26, as well as ours, had one or more lifestyle-related factors, including body mass index ≥ 25 kg/m2, diabetes mellitus, impaired glucose tolerance, hepatosteatosis, or alcohol consumption. In our patient, aging and daily alcohol consumption might have triggered the development of HCCs.

Keywords

Alcohol consumption Diabetes mellitus Body mass index Hepatosteatosis Sustained virological response 

Abbreviations

HCV

Hepatitis C virus

HCC

Hepatocellular carcinoma

IFNs

Interferons

SVR

Sustained virological response

DEB-TACE

Drug-eluting beads transcatheter arterial chemoembolization

CT

Computed tomography

BMI

Body mass index

HBsAg

Hepatitis B surface antigen

HBcAb

Hepatitis B core antibody

AST

Aspartate aminotransferase

ALT

Alanine aminotransferase

GGT

Gamma-glutamyl transpeptidase

AFP

Alpha-fetoprotein

BCLC

Barcelona clinic liver cancer

M2BPGi

Mac-2 binding protein glycosylation isomer

AUROC

Area under the receiver-operating characteristic curve

COI

Cut-off index

Notes

Acknowledgements

This study was supported by a Grant from the Ministry of Health, Labour and Welfare, Japan (H28-kansei-ippan-001).

References

  1. 1.
    Tada T, Kumada T, Toyoda H, et al. Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis. J Gastroenterol Hepatol. 2017;32:687–94.CrossRefGoogle Scholar
  2. 2.
    Makiyama A, Itoh Y, Kasahara A, et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer. 2004;101:1616–22.CrossRefGoogle Scholar
  3. 3.
    El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection. Hepatology. 2016;64:130–37.CrossRefGoogle Scholar
  4. 4.
    Iwasaki Y, Takaguchi K, Ikeda H, et al. Risk factors for hepatocellular carcinoma in hepatitis C patients with sustained virologic response to interferon therapy. Liver Int. 2004;24:603–10.CrossRefGoogle Scholar
  5. 5.
    Igarashi G, Endo T, Sawada N, et al. Development of hepatocellular carcinoma in chronic hepatitis c patients 20 years after achieving a sustained virological response with interferon therapy: a report of two cases. J Gen Fam Med. 2015;16:199–203.CrossRefGoogle Scholar
  6. 6.
    Okabe J, Fukuda K, Iwamoto T, et al. A case of cirrhosis with hepatitis C virus infection developing hepatocellular carcinoma 20 years after achieving sustained virological response to interferon therapy. Kanzo (Acta Hepatol Jpn). 2016;57:27–33 (in Japanese, abstract in English).CrossRefGoogle Scholar
  7. 7.
    Nakayama H, Iketani S, Okamoto D, et al. Long-term prognosis of patients with chronic hepatitis C who developed hepatocellular carcinoma after a sustained response to interferon therapy. Iwaki Kyoritsu Byoin Ihou (J Iwaki Kyoritsu Gen Hosp). 2013;34:12–21 (in Japanese).Google Scholar
  8. 8.
    Harai S, Kuratomi N, Fukazawa Y, et al. A case of hepatocellular carcinoma with portal vein tumor thrombosis and bone metastasis developed 20 years after successful interferon therapy to hepatitis C. Yamanashi Kenritsu Chuo Byoin Nenpo (J Yamanashi-ken Central Hosp. 2015; 41:68–70 (in Japanese).Google Scholar
  9. 9.
    Hirohata Y, Yoh Y, Nakamura Y, Kato T, Okamura R. Surgical treatment for hepatocellular carcinoma in a chronic hepatitis C patient 20 years after achieving a sustained virological response. Nippon Shokaki Geka Gakkai Zasshi (Jpn J Gastroenterol Surg). 2017;50:528–34 (in Japanese, abstract in English).CrossRefGoogle Scholar
  10. 10.
    Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289–93.CrossRefGoogle Scholar
  11. 11.
    Kuno A, Ikehara Y, Tanaka Y, et al. A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 2013;3:1065.CrossRefGoogle Scholar
  12. 12.
    Nagata H, Nakagawa M, Nishimura-Sakurai Y, et al. Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy. Hepatol Int. 2016;10:956–64.CrossRefGoogle Scholar
  13. 13.
    Sato T, Okada M, Masumoto A, Takeda N. A case of surgical treatment for hepatocellular carcinoma occurred 10 years after a successful interferon therapy in a patient with chronic hepatitis C. Rinsho to Kenkyu (Jpn J Clin Exp). 2005;82:342–43. (in Japanese).Google Scholar
  14. 14.
    Kobayashi M, Suzuki M, Yamada N, et al. A case of hepatocellular carcinoma developed ten years after successful interferon therapy for chronic hepatitis C. Sei Marianna Ika Daigaku Zasshi (St Marianna Med J). 2006;34:115–23 (in Japanese, abstract in English).Google Scholar
  15. 15.
    Sugunami F, Tomiyama Y, Ohmoto K, et al. Hepatocellular carcinoma occurring after 11 year-long sustained viral response to interferon therapy for chronic hepatitis C. Nippon Shokakibyo Gakkai Zasshi (Jpn J Soc Gastroenterol). 2007;104:809–14. (in Japanese, abstract in English).Google Scholar
  16. 16.
    Kimura Y, Tsuji K, Matsui T, et al. A case of synchronous double cancer of liver metastasis of thymoma and hepatocellular carcinomas, 10 years after achieving sustained virological response treated with peginterferon/ribavirin in chronic hepatitis C virus infection. Kanzo (Acta Hepatol Jpn). 2016;57:252–59 (in Japanese, abstract in English).CrossRefGoogle Scholar
  17. 17.
    Hanaoka J, Shimada M, Ikegami T, et al. A case of surgical treatment for hepatocellular carcinoma that developed in a chronic hepatitis C patient who had shown sustained virological response to interferon 11 years before. Kanzo (Acta Hepatol Jpn). 2008;49:248–54 (in Japanese, abstract in English).CrossRefGoogle Scholar
  18. 18.
    Nojiri K, Sugimoto K, Shiraki K, et al. Development of hepatocellular carcinoma in patients with chronic hepatitis C more than 10 years after sustained virological response to interferon therapy. Oncol Lett. 2010;1:427–30.CrossRefGoogle Scholar
  19. 19.
    Ito Y, Yamamoto N, Nakata R, et al. Delayed development of hepatocellular carcinoma during long-term follow-up after eradication of hepatitis C virus by interferon therapy. World J Gastroenterol. 2005;11:7218–21.CrossRefGoogle Scholar
  20. 20.
    Kawano Y, Egami K, Sasajima K, et al. A hepatocellular carcinoma developed following 12 years from sustained virologic response to interferon therapy in a patient with hepatitis C. Kanzo (Acta Hepatol Jpn). 2007;48:48–56 (in Japanese, abstract in English).CrossRefGoogle Scholar
  21. 21.
    Hayashi T, Tamori A, Nishikawa M, et al. Differences in molecular alterations of hepatocellular carcinoma between patients with a sustained virological response and those with hepatitis C virus infection. Liver Int. 2009;29:126–32.CrossRefGoogle Scholar
  22. 22.
    Sanefuji K, Kayashima H, Iguchi T, et al. Characterization of hepatocellular carcinoma developed after achieving sustained virological response to interferon therapy for hepatitis C. J Surg Oncol. 2009;99:32–7.CrossRefGoogle Scholar
  23. 23.
    Tsumura T, Takaki S, Aikata H, et al. A case of double cancer of the liver, cholangiocarcinoma and hepatocellular carcinoma detected in a patient with hepatitis C 13 years after diminution of HCV-RNA by interferon treatment. Nippon Shokakibyo Gakkai Zasshi (Jpn J Soc Gastroenterol). 2009;106:674–583 (in Japanese, abstract in English).Google Scholar
  24. 24.
    Yagura M, Tanaka A, Kamitsukasa H. A case of hepatocellular carcinoma who cleared hepatitis C virus with interferon therapy 13 years ago. Kanzo (Acta Hepatol Jpn). 2009;50:238–43 (in Japanese, abstract in English).CrossRefGoogle Scholar
  25. 25.
    Mashitani T, Yoshiji H, Yamazaki M, et al. Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: a case report. Cases J. 2009;2:18.CrossRefGoogle Scholar
  26. 26.
    Bertolini E, Bassi F, Fornaciari G. Deveopment of hepatocellular carcinoma in a non-cirrhotic, long-term responder to antiviral therapy, chronic hepatitis C patient: what kind of surveillance? Ann Gastroenterol. 2013;26:80–3.Google Scholar
  27. 27.
    Watanabe E, Koizumi Y, Hirooka M, et al. Hepatocellular carcinoma in a chronic hepatitis C patient 15 years after achieving a sustained virological response. Kanzo (Acta Hepatol Jpn). 2012;53:763–68 (in Japanese, abstract in English).CrossRefGoogle Scholar
  28. 28.
    Higuchi R, Yasuda H, Koda K, et al. Hepatocellular Carcinoma Development in Hepatitis-C-Sustained Virological Response to Interferon-Based Therapy After 15-Year Follow-Up. Nippon Gekakei Rengo Gakkaishi (J Jpn Coll Surgeons). 2011;36:66–71 (in Japanese, abstract in English).CrossRefGoogle Scholar
  29. 29.
    Takeuchi N, Tada H, Nishida Y, et al. Rapid growing hepatocellular carcinoma in a patient with chronic hepatitis C after 16 years of a sustained and complete response to interferon therapy. Kan Tan Sui. 2011;63:699–705 (in Japanese).Google Scholar
  30. 30.
    Saito M, Seo Y, Yano Y, et al. Development of a hepatocellular carcinoma in a chronic hepatitis C patient 18 years after achieving a sustained virological response to interferon therapy: case report and literature review. Clin J Gastroenterol. 2012;5:119–26.CrossRefGoogle Scholar
  31. 31.
    Ohshima K, Oba N, Kyoden Y, Iseki J, et al. A case of surgical treatment for hepatocellular carcinoma detected in a patient with chronic hepatitis C who had shown sustained virological response (SVR) to interferon 19 years before. Liver Cancer (Tokyo). 2012;18:23–35 (in Japanese, abstract in English).Google Scholar
  32. 32.
    Toyoda H, Tada T, Takaguchi K, et al. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan. J Viral Hepat. 2017;24:472–76.CrossRefGoogle Scholar
  33. 33.
    Asahina Y, Tsuchiya K, Nishimura T, et al. alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology. 2013;58:1253–62.CrossRefGoogle Scholar
  34. 34.
    Nirei K, Matsumura H, Kumakawa M, et al. Steatosis influences the clinical profiles and long-term outcomes of interferon-treated chronic hepatitis C and liver cirrhosis patients. Int J Med Sci. 2017;14:45–52.CrossRefGoogle Scholar
  35. 35.
    Nanba S, Ikeda F, Baba N, et al. Association of hepatic oxidative stress and iron dysregulation with HCC development after interferon therapy in chronic hepatitis C. J Clin Pathol. 2016;69:226–33.CrossRefGoogle Scholar
  36. 36.
    Whitfield JB, Zhu G, Heath AC, et al. Effects of alcohol consumption on indices of iron stores and of iron stores on alcohol intake markers. Alcohol Clin Exp Res. 2001;25:1037–45.CrossRefGoogle Scholar
  37. 37.
    Ikeda K, Marusawa H, Osaki Y, et al. Antibody to hepatitis B core antigen and risk for hepatitis C–related hepatocellular carcinoma: a prospective study. Ann Int Med. 2007;146:649–56.CrossRefGoogle Scholar
  38. 38.
    Kusumoto S, Tanaka Y, Mizokami M, et al. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol. 2009;90:13–23.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Gastroenterology 2018

Authors and Affiliations

  • Yuichi Yoshida
    • 1
    Email author
  • Miki Yonezawa
    • 1
  • Takuya Okamoto
    • 1
  • Yudai Fujiwara
    • 1
  • Akiko Suzuki
    • 1
  • Yuji Suzuki
    • 1
  • Kei Endo
    • 1
  • Keisuke Kakisaka
    • 1
  • Takayoshi Oikawa
    • 1
  • Hidekatsu Kuroda
    • 1
  • Akio Miyasaka
    • 1
  • Yasuhiro Takikawa
    • 1
  1. 1.Division of Hepatology, Department of Internal MedicineIwate Medical University School of MedicineMoriokaJapan

Personalised recommendations